Context: Neurotensin (NT), an intestinal peptide released by fat ingestion, promotes lipid absorption; higher circulating NT levels are associated with type 2 diabetes (T2D), obesity, and cardiovascular disease. Whether NT is related to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) has not been fully investigated. Objective: To study the relationship between plasma proneurotensin 1 to 117 (pro-NT), a stable fragment of the NT precursor hormone, and the presence/severity of NAFLD/NASH and to unravel correlates of increased pro-NT levels. Design/Setting/Participants: For this cross-sectional study, 60 obese individuals undergoing bariatric surgery for clinical purposes were recruited. The association between pro-NT and NAFLD was further investigated in 260 consecutive subjects referred to our outpatient clinics for metabolic evaluations, including liver ultrasonography. The study population underwent complete metabolic characterization; in the obese cohort, liver biopsies were performed during surgery. Main Outcome Measures: Plasma pro-NT levels in relation to NAFLD/NASH. Results: Obese subjects with biopsy-proven NAFLD (53%) had significantly higher plasma pro-NT than those without NAFLD (183.6 ± 81.4 vs 86.7 ± 56.8 pmol/L, P < 0.001). Greater pro-NT correlated with NAFLD presence (P < 0.001) and severity (P < 0.001), age, female sex, insulin resistance, and T2D. Higher pro-NT predicted NAFLD with an area under receiver operating characteristic curve of 0.836 [95% confidence interval (CI), 0.73 to 0.94; P < 0.001]. Belonging to the highest pro-NT quartile correlated with increased NAFLD risk (odds ratio, 2.62; 95% CI, 1.08 to 6.40) after adjustment for confounders. The association between higher pro-NT and NAFLD was confirmed in the second cohort independently from confounders. Conclusions: Increased plasma pro-NT levels identify the presence/severity of NAFLD; in dysmetabolic individuals, NT may specifically promote hepatic fat accumulation through mechanisms likely related to increased insulin resistance.
Context:Neurotensin (NT), an intestinal peptide released by fat ingestion, promotes lipid absorption; higher circulating NT levels are associated with type 2 diabetes (T2D), obesity, and cardiovascular disease. Whether NT is related to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) has not been fully investigated. Objective: To study the relationship between plasma proneurotensin 1 to 117 (pro-NT), a stable fragment of the NT precursor hormone, and the presence/severity of NAFLD/NASH and to unravel correlates of increased pro-NT levels. Design/Setting/Participants: For this cross-sectional study, 60 obese individuals undergoing bariatric surgery for clinical purposes were recruited. The association between pro-NT and NAFLD was further investigated in 260 consecutive subjects referred to our outpatient clinics for metabolic evaluations, including liver ultrasonography. The study population underwent complete metabolic characterization; in the obese cohort, liver biopsies were performed during surgery. Main Outcome Measures: Plasma pro-NT levels in relation to NAFLD/NASH. Results:Obese subjects with biopsy-proven NAFLD (53%) had significantly higher plasma pro-NT than those without NAFLD (183.6 ± 81.4 vs 86.7 ± 56.8 pmol/L, P < 0.001). Greater pro-NT correlated with NAFLD presence (P < 0.001) and severity (P < 0.001), age, female sex, insulin resistance, and T2D. Higher pro-NT predicted NAFLD with an area under receiver operating characteristic curve of 0.836 [95% confidence interval (CI), 0.73 to 0.94; P < 0.001]. Belonging to the highest pro-NT quartile correlated with increased NAFLD risk (odds ratio, 2.62; 95% CI, 1.08 to 6.40) after adjustment for confounders. The association between higher pro-NT and NAFLD was confirmed in the second cohort independently from confounders. Conclusions: Increased plasma pro-NT levels identify the presence/severity of NAFLD; in dysmetabolic individuals, NT may specifically promote hepatic fat accumulation through mechanisms likely related to increased insulin resistance.
Authors: Cecilia Ratner; Zhenyan He; Kaare V Grunddal; Louise J Skov; Bolette Hartmann; Fa Zhang; Annette Feuchtinger; Anette Bjerregaard; Christina Christoffersen; Matthias H Tschöp; Brian Finan; Richard D DiMarchi; Gina M Leinninger; Kevin W Williams; Christoffer Clemmensen; Birgitte Holst Journal: Diabetes Date: 2019-04-01 Impact factor: 9.461
Authors: X Ke; L Duan; F Gong; Y Zhang; K Deng; Y Yao; L Wang; F Feng; B Xing; H Pan; H Zhu Journal: J Endocrinol Invest Date: 2022-06-07 Impact factor: 5.467
Authors: Amal A Mohamed; Dina M Abo-Elmatty; Omnia Ezzat; Noha M Mesbah; Nada S Ali; Aliaa Sayed Abd El Fatah; Eman Alsayed; Mahmoud Hamada; Alshymaa A Hassnine; Sherief Abd-Elsalam; Ahmed Abdelghani; Mohamed Badr Hassan; Shaimaa A Fattah Journal: Diabetes Metab Syndr Obes Date: 2022-06-22 Impact factor: 3.249
Authors: Jin Li; Erwei Li; Rafael S Czepielewski; Jingyi Chi; Xiao Guo; Yong-Hyun Han; Daqing Wang; Luhong Wang; Bo Hu; Brian Dawes; Christopher Jacobs; Danielle Tenen; Samuel J Lin; Bernard Lee; Donald Morris; Adam Tobias; Gwendalyn J Randolph; Paul Cohen; Linus Tsai; Evan D Rosen Journal: Cell Metab Date: 2021-05-25 Impact factor: 31.373
Authors: Stephanie Rock; Xian Li; Jun Song; Courtney M Townsend; Heidi L Weiss; Piotr Rychahou; Tianyan Gao; Jing Li; B Mark Evers Journal: PLoS One Date: 2019-03-27 Impact factor: 3.240
Authors: Beatriz Villar; Laia Bertran; Carmen Aguilar; Jessica Binetti; Salomé Martínez; Fàtima Sabench; Monica Real; David Riesco; Marta París; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet Journal: Metabolites Date: 2021-06-10